Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NePtune: Neoadjuvant Olaparib + LHRH Agonist in High-Risk Prostate Cancer
NCT05498272Phase 2Active, not recruiting
- Start
- Feb 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in prostate cancer (PCa). Primary endpoints: Pathological Complete Response rate at 4 years and Minimal Residual Disease rate at 4 years. Started Feb 2023; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05498272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498272.